Research on GGT-responsive drug carrier with active transport effect

Although a great quantity research has been done on cancer nano-drug carriers, how to deliver more cancer nano-drugs to tumor sites accurately and then endocytosis by cells is still a key problem in the process of cancer treatment. Since the concentration of gamma-glutamyl transpeptidase (GGT) in the microenvironment will be greatly increased when the liver, kidney, and other organs become cancerous, we have designed a polymer nanomicelle as drug carrier that can respond to the GGT in the tumor microenvironment. When the drug delivery system participates in blood circulation through the vascular wall cells to the tumor tissue, the overexpressed GGT on the surface of the cancer cells will recognize and cut the gamma-glutamyl group on the carrier, and the primary amines will be released to make the system with weak positive charge, which not only improves the carrier's active transport ability for nanodrugs, but also improves the cell's endocytosis ability for nano-drugs, so as to realize the release of nano-drugs in cancer cells. What's more, the positive charge on the surface of the carrier also improves the permeability of the carrier in the tumor tissue, so that the cancer cells in the hypoxic area can also endocytosis drugs.